Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Buprenex with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol).
The MOU is developed through a process of negotiation and mutual assent, finalized through acceptance of the MOU instrument, and approved by the appropriate agency representatives who signify such approval by signing the MOU.
Negotiations are scheduled to start in January 1995 for MOUs to cover the 1995-96 fiscal year and, possibly, other years as well. State law requires that the administration and employee representatives endeavor to reach agreements before the Legislature adopts a budget act for the ensuing fiscal year.